Clinical Trials Logo

Clinical Trial Summary

Vitamin K antagonists (VKAs) are used to reduce the risk of stroke (cerebral vascular dysfunction) in AF patients. However, VKAs interact with drugs/food and the drug level is influenced by worsening of renal function, liver congestion or hemodynamic alterations in acute decompensated heart failure (ADHF). New oral anticoagulants (rivaroxaban, apixaban, dabigatran) are alternatives to VKA, such as warfarin. In post hoc analysis of ROCKET AF trial, 63.7% patients had HF and treatment-related outcomes were similar in patients with and without HF (Circulation HF. 2013; 6:740-7). So rivaroxaban 20 mg daily (or 15 mg daily in patients with creatinine clearance 30-49 mL/min) was safe in nonvalvular AF patients with HF. However, the clinical effect and safety of rivaroxaban were largely unknown in acute decompensated heart failure (ADHF) patients with atrial fibrillation (AF).

ROAD HF-AF is the exploratory study to assess the change of surrogate markers (hsTn, d-dimer) when treated with rivaroxaban vs. warfarin and to strengthen the basis for future biomarker-based therapy in ADHF patients

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT03490994
Study type Interventional
Source Yonsei University
Contact Seok-Min Kang, MD
Phone 82-2-2228-8450
Status Recruiting
Phase Phase 4
Start date April 10, 2018
Completion date January 2020

See also
  Status Clinical Trial Phase
Terminated NCT02151383 - Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure Phase 2
Completed NCT02135835 - A Study to Evaluate the Efficacy and Safety of Shenfu Zhusheye in Patients With Acute Heart Failure Phase 4
Completed NCT02122640 - Evaluation of Acute Cardiogenic Dyspnoea With Thorax Echography and Pro-BNP in the Emergency Department N/A
Not yet recruiting NCT01211886 - Utility of Brain Natriuretic Peptide (BNP) in Patients With Type IV Cardio-renal Syndrome Admitted to the Intensive Care Unit (ICU) N/A
Completed NCT01193998 - Impact of Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department N/A
Active, not recruiting NCT00512759 - Goal-directed Afterload Reduction in Acute Congestive Cardiac Decompensation Study Phase 4
Recruiting NCT03157219 - Manipal Heart Failure Registry (MHFR) N/A
Enrolling by invitation NCT02258984 - Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial N/A
Completed NCT02141607 - Evolution of Molecular Biomarkers in Acute Heart Failure Induced by Shock
Completed NCT01870778 - Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF Phase 3
Recruiting NCT03720288 - Acetazolamide in Patients With Acute Heart Failure Phase 3
Recruiting NCT03717636 - Early or Non-revoked in Hospital-day in Patients With Acute Heart Failure N/A
Not yet recruiting NCT03681379 - Pharmacokinetics of Levosimendan in Pediatric Intensive Care Units
Recruiting NCT03161158 - PURE-HF: Peripheral Ultrafiltration for the RElief From Congestion in Heart Failure N/A
Not yet recruiting NCT03683212 - Early and Comprehensive Care Bundle in Elderly for Acute Heart Failure: a Stepped Wedge Cluster Randomized Trial N/A
Recruiting NCT03110042 - HILO-HF Registry: High Versus Low SpO2 Oxygen Therapy in Patients With Acute Heart Failure
Completed NCT02350114 - An Observational Study of the Functional Capacity of Heart Failure N/A
Recruiting NCT01704131 - Levosimendan Pharmacokinetics in Children N/A
Completed NCT00561483 - Sequential Cystatin C Levels and Renal Impairment in Acute Heart Failure N/A
Recruiting NCT03736421 - Observational Study to Evaluate Peripheral IntraVenous Analysis (PIVA) in Euvolemic, Hypovolemic, and Hypervolemic Emergency Department Patients